SentoClone Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 28

Employees

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 2

SentoClone General Information

Description

Operator of a medical research company intended to fight cancer. The company develops immunotherapy where the immune system is activated and strengthened to fight cancer, enabling healthcare providers to treat cancer based on the ex vivo cultivation and activation of T-cells.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Allen 5
  • 172 66 Sundbyberg
  • Sweden
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Allen 5
  • 172 66 Sundbyberg
  • Sweden

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

SentoClone Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore SentoClone‘s full profile, request access.

Request a free trial

SentoClone Patents

SentoClone Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2009270434-A1 Composition comprising in vitro expanded t-lymphocytes and vessel formation inhibitors suitable in the treatment of cancer Active 18-Jul-2008
AU-2009270434-B2 Composition comprising in vitro expanded t-lymphocytes and vessel formation inhibitors suitable in the treatment of cancer Inactive 18-Jul-2008
CA-2730050-A1 Composition comprising in vitro expanded t-lymphocytes and vessel formation inhibitors suitable in the treatment of cancer Inactive 18-Jul-2008
EP-2364163-A1 Composition comprising in vitro expanded t-lymphocytes and vessel formation inhibitors suitable in the treatment of cancer Active 18-Jul-2008
EP-2364163-B1 Composition comprising in vitro expanded t-lymphocytes and vessel formation inhibitors suitable in the treatment of cancer Inactive 18-Jul-2008 C12N5/0636
To view SentoClone’s complete patent history, request access »

SentoClone Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

SentoClone Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore SentoClone‘s full profile, request access.

Request a free trial

SentoClone FAQs

  • When was SentoClone founded?

    SentoClone was founded in 2004.

  • Where is SentoClone headquartered?

    SentoClone is headquartered in Sundbyberg, Sweden.

  • What is the size of SentoClone?

    SentoClone has 28 total employees.

  • What industry is SentoClone in?

    SentoClone’s primary industry is Drug Discovery.

  • Is SentoClone a private or public company?

    SentoClone is a Private company.

  • What is SentoClone’s current revenue?

    The current revenue for SentoClone is .

  • Who are SentoClone’s investors?

    Vinnova has invested in SentoClone.

  • When was SentoClone acquired?

    SentoClone was acquired on 01-Jan-2010.

  • Who acquired SentoClone?

    SentoClone was acquired by Sinorda Biomedicine.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process